Roche's Genentech Announces New 72-Week Data From BALATON And COMINO, Evaluating Vabysmo® In Macular Edema Due To Branch And Central Retinal Vein Occlusion
Portfolio Pulse from Benzinga Newsdesk
Genentech, a Roche subsidiary, announced new 72-week data from BALATON and COMINO studies evaluating Vabysmo for macular edema due to retinal vein occlusion (RVO). The data showed that Vabysmo sustained significant drying of retinal fluid and allowed up to 60% of patients to extend treatment intervals to three or four months. These results will be presented at the Angiogenesis, Exudation, and Degeneration 2024 conference. Vabysmo is approved in the U.S. for RVO and in over 90 countries for wet AMD and DME.
February 01, 2024 | 7:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roche's positive data for Vabysmo in treating RVO may lead to increased usage and extended treatment intervals, potentially boosting sales and strengthening its market position.
The positive long-term data for Vabysmo is likely to increase trust in the drug's efficacy and safety, leading to greater adoption by healthcare providers and potentially higher sales for Roche. This can have a favorable impact on Roche's stock in the short term as investors may anticipate growth in revenue from this product.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90